domingo, 20 de abril de 2025

Osimertinib OS Benefit Persists Among Patients With EGFR+ NSCLC Sharon Worcester, MA March 31, 2025

https://www.medscape.com/viewarticle/osimertinib-os-benefit-persists-among-patients-egfr-nsclc-2025a10007mj?ecd=WNL_conf_onc_ELCC-SPON_250420_MSCPEDIT_etid7368804&uac=148436CN&impID=7368804

No hay comentarios:

Publicar un comentario